Comparative Pharmacology
Head-to-head clinical analysis: BLENREP versus LONSURF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLENREP versus LONSURF.
BLENREP vs LONSURF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) on multiple myeloma cells. The monoclonal antibody component binds to BCMA, leading to internalization and release of the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule polymerization and induces apoptosis.
LONSURF (trifluridine and tipiracil) is a combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil. Trifluridine incorporates into DNA and inhibits cell proliferation, while tipiracil increases trifluridine exposure by inhibiting its degradation by thymidine phosphorylase.
2.5 mg/kg (actual body weight) intravenously over 30 minutes on day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Adults: 35 mg/m2 orally twice daily on days 1-5 and 8-12 of each 28-day cycle.
None Documented
None Documented
The terminal elimination half-life of belantamab mafodotin is approximately 12 days (range 9-19 days). This supports a dosing interval of every 3 weeks, allowing for drug clearance between cycles while maintaining therapeutic exposure.
Trifluridine: terminal half-life approximately 1.4-2.1 hours; tipiracil: terminal half-life approximately 2-3 hours. Clinical context: short half-lives necessitate twice-daily dosing on Days 1-5 and 8-12 of a 28-day cycle.
Blenrep (belantamab mafodotin) is eliminated primarily via catabolism, with no significant renal or biliary excretion of intact drug. The small molecule toxin, monomethyl auristatin F (MMAF), is excreted via feces (72%) and urine (28%) after release from the antibody conjugate.
Primarily renal: tipiracil is excreted unchanged in urine (approximately 50% of dose); trifluridine is eliminated via metabolism and renal excretion (as metabolites and unchanged drug). Fecal elimination accounts for <3% of total clearance.
Category C
Category C
Antineoplastic, Monoclonal Antibody
Antineoplastic